Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amivas, LLC
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
Sponsors of several new medicines are set to learn if their products are on track for pan-EU approval. One product on the list is Pfizer/Lilly’s osteoarthritis drug, tanezumab, which recently ran into trouble in the US.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.